Ads
related to: benign prostatic hyperplasia clinical guidelines list
Search results
Results From The WOW.Com Content Network
The International Prostate Symptom Score (IPSS) is an eight-question written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. [1] Symptoms may include frequent urination , trouble starting to urinate, weak stream, inability to urinate , or loss of bladder control . [ 1 ]
The American Urological Association (AUA) guidelines for the treatment of BPH from 2018 list minimally invasive therapies including TUMT - but not TUNA - as acceptable alternatives for certain patients with BPH. [11] However, the European Association of Urology (EAU) has - as of 2019 - removed both TUMT and TUNA from its guidelines. [15]
Around one third of men will develop urinary tract (outflow) symptoms, of which the principal underlying cause is benign prostatic hyperplasia. [26] Once symptoms arise, their progress is variable and unpredictable with about one third of patients improving, one third remaining stable and one third deteriorating. [citation needed]
Prostatic artery embolization (PAE, or prostate artery embolisation) is a non-surgical technique for treatment of benign prostatic hyperplasia (BPH). [1]The procedure involves blocking the blood flow of small branches of the prostatic arteries using microparticles injected via a small catheter, [2] to decrease the size of the prostate gland to reduce lower urinary tract symptoms.
Diagnosis involves ruling out other potential causes of the symptoms such as bacterial prostatitis, benign prostatic hyperplasia, overactive bladder, and cancer. [2] [5] Recommended treatments include multimodal therapy, physiotherapy, and a trial of alpha blocker medication or antibiotics in certain newly diagnosed cases. [6]
The first effective treatment for benign prostatic hyperplasia (BPH) was a non-selective alpha blocker phenoxybenzamine which was irreversible. Dibenzyline was the first brand name marketed. Today phenoxybenzamine is not the first choice due to many side effects like lowering blood pressure. [2]
While there are limited clinical α-blocker uses, in which most α-blockers are used for hypertension or benign prostatic hyperplasia, α-blockers can be used to treat a few other diseases, such as Raynaud's disease, congestive heart failure (CHF), pheochromocytoma, and erectile dysfunction.